| Dr Amola S Bagri, MD | |
|
4701 Old Shepard Pl Ste 100, Plano, TX 75093-5295 | |
| (214) 358-2300 | |
| (214) 579-6941 |
| Full Name | Dr Amola S Bagri |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 25 Years |
| Location | 4701 Old Shepard Pl Ste 100, Plano, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265410849 | NPI | - | NPPES |
| L6274 | Other | TX | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | L6274 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc Dialysis Services Terrell | Terrell, TX | Dialysis facility |
| Dialysis Services Of Allen | Allen, TX | Dialysis facility |
| Fmc Dialysis Services Of Mckinney | Mckinney, TX | Dialysis facility |
| Collin County Dialysis Center | Plano, TX | Dialysis facility |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dallas Nephrology Associates | 3870403819 | 128 |
News Archive
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
VIVUS, Inc. today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED).
University of Rochester Medical Center researchers believe they have identified a potential new means of treating some of the most severe genetic diseases of childhood, according to a study in PLOS Biology.
Reporting for Kaiser Health News, Susan Jaffe writes: Shopping for health insurance next year will be easier when hundreds of health insurers and employers use the same simple forms unveiled Wednesday by the Obama administration, consumer advocates and government officials say. But the new materials, required by the 2010 health law, are still a work in progress.
NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced its first quarter 2010 financial results.
› Verified 3 days ago
| Entity Name | Dallas Nephrology Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861440109 PECOS PAC ID: 3870403819 Enrollment ID: O20040624000638 |
News Archive
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
VIVUS, Inc. today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED).
University of Rochester Medical Center researchers believe they have identified a potential new means of treating some of the most severe genetic diseases of childhood, according to a study in PLOS Biology.
Reporting for Kaiser Health News, Susan Jaffe writes: Shopping for health insurance next year will be easier when hundreds of health insurers and employers use the same simple forms unveiled Wednesday by the Obama administration, consumer advocates and government officials say. But the new materials, required by the 2010 health law, are still a work in progress.
NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced its first quarter 2010 financial results.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amola S Bagri, MD 1505 Lbj Fwy Ste 700, Dallas, TX 75234-6065 Ph: (214) 358-2300 | Dr Amola S Bagri, MD 4701 Old Shepard Pl Ste 100, Plano, TX 75093-5295 Ph: (214) 358-2300 |
News Archive
TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.
VIVUS, Inc. today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED).
University of Rochester Medical Center researchers believe they have identified a potential new means of treating some of the most severe genetic diseases of childhood, according to a study in PLOS Biology.
Reporting for Kaiser Health News, Susan Jaffe writes: Shopping for health insurance next year will be easier when hundreds of health insurers and employers use the same simple forms unveiled Wednesday by the Obama administration, consumer advocates and government officials say. But the new materials, required by the 2010 health law, are still a work in progress.
NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced its first quarter 2010 financial results.
› Verified 3 days ago
Yinghui Liu, MD, PHD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4020 Hedgcoxe Rd, Ste 700, Plano, TX 75024 Phone: 972-618-7800 Fax: 972-618-7900 | |
Dr. Mukesh Kumar D Delvadiya, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6300 W. Parker Road, Suite 123, Mob Ii, Plano, TX 75093 Phone: 972-398-2899 Fax: 972-398-2837 | |
Dr. Ashesh Bakulesh Parikh, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6300 W Parker Rd Ste 322, Plano, TX 75093 Phone: 972-981-7870 Fax: 972-981-7886 | |
Sean Allan Townsend, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4716 Alliance Blvd, Suite 500, Plano, TX 75093 Phone: 469-800-6000 Fax: 469-800-6052 | |
Dr. Vijay Sitharam Ramanath, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6124 W Parker Rd, Suite 536, Plano, TX 75093 Phone: 972-378-9560 Fax: 844-290-4363 | |
Samuel Afenir Piga, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 3105 W 15th St, Suite E, Plano, TX 75075 Phone: 469-467-9755 Fax: 972-801-9917 | |
Dr. Maria Love Lee, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6200 W Parker Rd, Plano, TX 75093 Phone: 972-293-5151 Fax: 972-981-3967 |